The objective of this systematic review is to synthesise the best available evidence on the association between treatment with selective serotonin reuptake inhibitors (SSRI) and suicidality/suicide in older people over the age of 60 years who suffer from major depression.
Background
Suicide is a significant public health issue. 1 It is the 15th leading cause of death in Australia according to the Australian Bureau of Statistics and elderly suicide rate has been increasing since 2008. 2 As at 2008, the age specific mean death rate for suicide in males over the age of 65 years was 23.5/100,000 and for females, 4.4/100,000. In the population aged 30-45 years, the rate was only slightly higher with 27.7/100,000 for males and 6.4/100,000 for females. 2 Suicide is a complex multicausal human behaviour related to several psychiatric-medical, psychosocial and demographic suicide risk factors. 3 Depression is one of the leading causes of suicide in older people and up to 75% of older people who died by suicide reportedly visit a physician within a month before their death.
following nine symptoms must be present almost daily over the previous two weeks: 1 harms often require data from observational studies and unpublished trials. 25 To avoid confusion or misleading conclusions, Chou et al 26 provided definitions for commonly used terms for harms reporting. Systematic reviews that combine benefits and harms assessment will need to incorporate and integrate the best information from both randomised trials and observational studies 27 .
Selective serotonin reuptake inhibitors are the first line antidepressant medication for older depressed and suicidal patients. It is necessary to inform clinicians with the best available evidence on the effect of SSRI on suicide risk in older people with major depression. The aim of this study is to synthesise the best available evidence, including both experimental and observational data, on the association between treatment with SSRIs and suicidality/suicide in older people over the age of 60 years.
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Inclusion criteria

Types of participants
This review will consider older patients aged over 60 years, regardless of gender, sex or race who fulfilled the DSM IV or equivalent diagnostic criteria for Major Depressive Disorder without psychotic features. The review will consider both community and hospitalised older patients with stable medical co morbidities.
Types of intervention(s)/phenomena of interest
The focus of this review is on the association between treatment with SSRIs and the harmful outcome of suicidality/suicide. The review will consider treatments using any SSRI medication which includes fluoxetine, sertraline, paroxetine, citalopram, escitalopram and fluvoxamine given orally with clinically effective dose recommended by the manufacturer for older people for a minimum duration of treatment of four weeks.
Types of outcomes
The main outcomes of interest are suicidal ideation, number of suicide attempts and mortality due to suicide. For this systematic review, the term 'suicide attempt' refers to potentially self-injurious behaviour with a nonfatal outcome, for which there is evidence (either implicit or explicit) that the person intended at some (nonzero) level to kill himself/herself. 28 Suicide ideation may be measured 
Types of studies
This review will consider both experimental and epidemiological study designs including randomised controlled trials, non-randomised controlled trials, quasi-experimental, before and after studies, prospective and retrospective cohort studies, and case control studies.
Search strategy
The search strategy aims to find both published and unpublished studies in English language. The search will employ a three step search strategy. An initial search with PubMed will be undertaken using initial key words in various combinations. Initial key words to be used are older people, old age, geriatric patients, major depression, depression, late-life depression, depression outcome, suicide ideation, change in suicidal ideation, completed suicide, attempted suicide, suicide outcome, randomised double blind placebo controlled trials, randomized controlled trials, placebo controlled trials, clinical trial, experimental study, SSRIs, dual action antidepressants and meta-analysis. This will be followed by analysis of the text words contained in the title, abstract and the index terms used to describe the most relevant articles. Then a second search will be undertaken using all identified keywords and index terms across all databases listed below. Finally, the reference list of all identified reports and articles will be searched for additional studies. When necessary, additional information will be sought by contacting authors or drug manufacturers. 
Assessment of methodological quality
The quality of papers selected for retrieval will be assessed by two independent reviewers for methodological validity prior to inclusion in the review using standardised critical appraisal instruments from the Joanna Briggs Institute Meta Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI). An accepted appraisal tool specific for evaluation of treatment harms in primary studies will also be used to assess study quality 29 (Appendix I). Any disagreements that arise between the reviewers will be resolved through discussion or with a third reviewer.
Data collection
Data from main articles included in this systematic review will be extracted using the standardised data extraction tool from JBI-MAStARI (Appendix II).
Data synthesis
Quantitative data will, where possible be pooled in statistical meta-analysis using RevMan v5.1 software (The Cochrane Collaboration). 30 Effect sizes expressed as odds ratios and relative risks (for categorical data) and weighted mean differences (for continuous data) and their 95% confidence intervals will be calculated. Heterogeneity will be assessed statistically using the standard Chi-square and also explored using subgroup analyses based on the different study designs included in this review. Where statistical pooling is not possible the findings will be presented in narrative form including tables and figures to aid in data presentation where appropriate.
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